With respect to Spry2, data generated on RNA level clearly points towards an upregulation of this Spry member in GBM when compared to non-tumor tissue [25], while a study exploring protein levels in immunohistochemistry suggests downregulation of Spry2 in higher malignant brain cancers when compared to lower graded tumors [41]. The gene discussed is SPRY2; the disease is glioblastoma.